Centralization of care for patients with advanced-stage ovarian cancer: A cost-effectiveness analysis

Cancer

Volumn 109, Issue 8, 2007, Pages 1513-1522

  Bristow, Robert E ^a,c   Santillan, Antonio ^a   Diaz Montes, Teresa P ^a   Gardner, Ginger J ^a   Giuntoli II, Robert L ^a   Meisner, Benjamin C ^a   Frick, Kevin D ^b   Armstrong, Deborah K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Kelly Gynecologic Oncology Service   (United States)

Author keywords

Centralized care; Cost effectiveness; Ovarian cancer; Quality adjusted life years

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HOSPITAL COST; HUMAN; METABOLIC DISORDER; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARIECTOMY; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TERTIARY HEALTH CARE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CENTRALIZED HOSPITAL SERVICES; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUALITY OF LIFE; REFERRAL AND CONSULTATION;

EID: 34247099296     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22561     Document Type: Article

References (53)

1. IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (2002 Estimates). Available at URL: http://www-dep.iarc.fr/ Accessed 2006.
2. Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepard JH. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 1998;3:75-102.
3. Hunter RW, Alexandre ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol. 1992;166:504-511.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
5. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994;70:363-370.
6. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203-209.
7. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999;106:1130-1136.
8. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol. 2002;84:36-42.
9. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102:499-505.
10. Engelen MJ, Kos HE, Willemse PHB, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106:589-598.
11. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16:11-17.
12. Ioka A, Tsukuma H, Ajiki W, Oshima A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 2004;95:233-237.
13. Manuel MR, Chen LM, Caughey AB, Subak LL. Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends. Gynecol Oncol. 2004;93:1-4.
14. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol. 1985;20;190-195.
15. Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986;24:1-8.
16. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783-788.
17. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol. 1988;6:983-989.
18. Rose PG. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol. 1992;166;843-846.
19. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer. 1994;74:656-663.
20. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 1994;53:326-330.
21. Van Dam PA, Tjalma W, Weyler J, van Oosterom AT, Buyaert P. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol. 1996;174:943-950.
22. Michel G, DeIaco P, Castaigne D, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1997;1:9-15.
23. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103-108.
24. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian cancer? Gynecol Oncol. 1997;67:208-214.
25. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390-396.
26. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
27. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77-85.
28. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559-564.
29. Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol. 1983;3:370-380.
30. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACVA study. Gynecol Oncol. 1990;38:203-209.
31. Unzelman RF. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital. Am J Obstet Gynecol. 1992;166:1663-1671.
32. Del Campo JM, Felip E, Rubio D, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 1994;53:27-32.
33. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175-180.
34. Sengupta PS, Jayson GC, Slade RJ, Eardley A, Radford JA. An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer. 1999;80:444-447.
35. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
36. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-115.
37. Bureau of Labor Statistics. Available at URL: http:// www.bls.gov/news.release/empsit.t16.htm Accessed 2006.
38. Bureau of Labor Statistics. Available at URL: http:// www.bls.gov/news.release/empit.t02.htm Accessed 2006.
39. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialization on patient survival in ovarian carcinoma. Br J Cancer. 1994;70:1014-1017.
40. [No authors listed.] NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273:491-497.
41. Woodman C, Baghdady A, Collins S, Clyma JA. What changes in the organization of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol. 1997;104:135-139.
42. Petignat P, Vajda D, Joris F, Obrist R. Surgical management of epithelial ovarian cancer at community hospitals: a population-based study. J Surg Oncol. 2000;75:19-23.
43. Olaitan A, Weeks J, Mocroft A, Smith J, Howe K, Murdoch J. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer. 2001;85:1824-1830.
44. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidenced based review. Gynecol Oncol. 2005;99:447-461.
45. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000:18:2327-2340.
46. Kumpulainen S, Grenman S, Kyyronen P. Pukkala E, Sankila R. Evidence of benefit from centralized treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int J Cancer. 2002;102:541-544.
47. Hoskins W, Rice L, Rubin S. Ovarian cancer surgical practice guidelines. Oncology. 1997;11:896-904.
48. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-654.
49. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-1090.
50. McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 1993;71:628-633.
51. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma I. A patient care evaluation study by the American College of Surgeons. Cancer. 1993;71:1629-1638.
52. Grossi M, Quinn MA, Thursfield VJ, et al. Ovarian cancer: patterns of care in Victoria 1993-1995. Med J Aust. 2002;177:11-16.
53. Bristow RE, Zahurak ML, del Carmen MG, et al. Ovarian cancer surgery in Maryland: volume based access to care. Gynecol Oncol. 2004;93:353-360.